Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
42
SMLR Quote, Financials, Valuation and Earnings
Last price:
$20.71
Seasonality move
:
2.78%
Day range:
$20.18 - $22.00
52-week range:
$14.89 - $66.50
Dividend yield:
0%
P/E ratio:
7.65x
P/S ratio:
6.93x
P/B ratio:
0.70x
Volume:
576K
Avg. volume:
444.6K
1-year change:
-63.93%
Market cap:
$322.3M
Revenue:
$56.3M
EPS (TTM):
$2.78
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SMLR
Semler Scientific, Inc.
|
$3.4M | -$0.54 | -72.52% | -91.67% | $65.67 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | 8.36% | 39.86% | $14.20 |
|
VNRX
VolitionRX Ltd.
|
$714.1K | -$0.04 | 272.5% | -33.67% | $2.20 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$30.8M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SMLR
Semler Scientific, Inc.
|
$21.26 | $65.67 | $322.3M | 7.65x | $0.00 | 0% | 6.93x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8100 | $12.3077 | $208.9M | -- | $0.00 | 0% | 190.53x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.77 | $14.20 | $178.3M | 33.54x | $0.00 | 0% | 1.32x |
|
VNRX
VolitionRX Ltd.
|
$0.28 | $2.20 | $34M | -- | $0.00 | 0% | 18.97x |
|
VTAK
Catheter Precision, Inc.
|
$2.01 | -- | $2.5M | 0.40x | $0.00 | 0% | 9.45x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.71 | $1.50 | $99.4M | 69.62x | $0.00 | 0% | 0.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SMLR
Semler Scientific, Inc.
|
4.17% | 2.857 | 4.4% | 0.49x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | 0.156 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SMLR
Semler Scientific, Inc.
|
$6.9M | -$5.4M | 18.02% | 18.3% | -71.95% | -$81.9M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Semler Scientific, Inc. vs. Competitors
-
Which has Higher Returns SMLR or CATX?
Perspective Therapeutics, Inc. has a net margin of -732.34% compared to Semler Scientific, Inc.'s net margin of -12425.36%. Semler Scientific, Inc.'s return on equity of 18.3% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital SMLRSemler Scientific, Inc.91.51% $1.07 $479.7M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About SMLR or CATX?
Semler Scientific, Inc. has a consensus price target of $65.67, signalling upside risk potential of 208.87%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 338%. Given that Perspective Therapeutics, Inc. has higher upside potential than Semler Scientific, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Semler Scientific, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMLRSemler Scientific, Inc.2 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is SMLR or CATX More Risky?
Semler Scientific, Inc. has a beta of 1.316, which suggesting that the stock is 31.636% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock SMLR or CATX?
Semler Scientific, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SMLR or CATX?
Semler Scientific, Inc. quarterly revenues are $7.5M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Semler Scientific, Inc.'s net income of $16.9M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Semler Scientific, Inc.'s price-to-earnings ratio is 7.65x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific, Inc. is 6.93x versus 190.53x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMLRSemler Scientific, Inc.6.93x 7.65x $7.5M $16.9M CATXPerspective Therapeutics, Inc.190.53x -- $209K -$26M
-
Which has Higher Returns SMLR or INFU?
InfuSystem Holdings, Inc. has a net margin of -732.34% compared to Semler Scientific, Inc.'s net margin of 6.19%. Semler Scientific, Inc.'s return on equity of 18.3% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital SMLRSemler Scientific, Inc.91.51% $1.07 $479.7M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About SMLR or INFU?
Semler Scientific, Inc. has a consensus price target of $65.67, signalling upside risk potential of 208.87%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 61.92%. Given that Semler Scientific, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Semler Scientific, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMLRSemler Scientific, Inc.2 0 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is SMLR or INFU More Risky?
Semler Scientific, Inc. has a beta of 1.316, which suggesting that the stock is 31.636% more volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock SMLR or INFU?
Semler Scientific, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SMLR or INFU?
Semler Scientific, Inc. quarterly revenues are $7.5M, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Semler Scientific, Inc.'s net income of $16.9M is higher than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Semler Scientific, Inc.'s price-to-earnings ratio is 7.65x while InfuSystem Holdings, Inc.'s PE ratio is 33.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific, Inc. is 6.93x versus 1.32x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMLRSemler Scientific, Inc.6.93x 7.65x $7.5M $16.9M INFUInfuSystem Holdings, Inc.1.32x 33.54x $36.5M $2.3M
-
Which has Higher Returns SMLR or VNRX?
VolitionRX Ltd. has a net margin of -732.34% compared to Semler Scientific, Inc.'s net margin of -862.39%. Semler Scientific, Inc.'s return on equity of 18.3% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SMLRSemler Scientific, Inc.91.51% $1.07 $479.7M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About SMLR or VNRX?
Semler Scientific, Inc. has a consensus price target of $65.67, signalling upside risk potential of 208.87%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 694.8%. Given that VolitionRX Ltd. has higher upside potential than Semler Scientific, Inc., analysts believe VolitionRX Ltd. is more attractive than Semler Scientific, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMLRSemler Scientific, Inc.2 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is SMLR or VNRX More Risky?
Semler Scientific, Inc. has a beta of 1.316, which suggesting that the stock is 31.636% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.
-
Which is a Better Dividend Stock SMLR or VNRX?
Semler Scientific, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SMLR or VNRX?
Semler Scientific, Inc. quarterly revenues are $7.5M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Semler Scientific, Inc.'s net income of $16.9M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Semler Scientific, Inc.'s price-to-earnings ratio is 7.65x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific, Inc. is 6.93x versus 18.97x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMLRSemler Scientific, Inc.6.93x 7.65x $7.5M $16.9M VNRXVolitionRX Ltd.18.97x -- $627.3K -$5.4M
-
Which has Higher Returns SMLR or VTAK?
Catheter Precision, Inc. has a net margin of -732.34% compared to Semler Scientific, Inc.'s net margin of -1037.17%. Semler Scientific, Inc.'s return on equity of 18.3% beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital SMLRSemler Scientific, Inc.91.51% $1.07 $479.7M VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About SMLR or VTAK?
Semler Scientific, Inc. has a consensus price target of $65.67, signalling upside risk potential of 208.87%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1790.6%. Given that Catheter Precision, Inc. has higher upside potential than Semler Scientific, Inc., analysts believe Catheter Precision, Inc. is more attractive than Semler Scientific, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMLRSemler Scientific, Inc.2 0 0 VTAKCatheter Precision, Inc.0 0 0 -
Is SMLR or VTAK More Risky?
Semler Scientific, Inc. has a beta of 1.316, which suggesting that the stock is 31.636% more volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.392, suggesting its less volatile than the S&P 500 by 239.195%.
-
Which is a Better Dividend Stock SMLR or VTAK?
Semler Scientific, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SMLR or VTAK?
Semler Scientific, Inc. quarterly revenues are $7.5M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. Semler Scientific, Inc.'s net income of $16.9M is higher than Catheter Precision, Inc.'s net income of -$2.3M. Notably, Semler Scientific, Inc.'s price-to-earnings ratio is 7.65x while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific, Inc. is 6.93x versus 9.45x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMLRSemler Scientific, Inc.6.93x 7.65x $7.5M $16.9M VTAKCatheter Precision, Inc.9.45x 0.40x $226K -$2.3M
-
Which has Higher Returns SMLR or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -732.34% compared to Semler Scientific, Inc.'s net margin of 3.93%. Semler Scientific, Inc.'s return on equity of 18.3% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital SMLRSemler Scientific, Inc.91.51% $1.07 $479.7M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About SMLR or XTNT?
Semler Scientific, Inc. has a consensus price target of $65.67, signalling upside risk potential of 208.87%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 111.24%. Given that Semler Scientific, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Semler Scientific, Inc. is more attractive than Xtant Medical Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMLRSemler Scientific, Inc.2 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is SMLR or XTNT More Risky?
Semler Scientific, Inc. has a beta of 1.316, which suggesting that the stock is 31.636% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock SMLR or XTNT?
Semler Scientific, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SMLR or XTNT?
Semler Scientific, Inc. quarterly revenues are $7.5M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Semler Scientific, Inc.'s net income of $16.9M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Semler Scientific, Inc.'s price-to-earnings ratio is 7.65x while Xtant Medical Holdings, Inc.'s PE ratio is 69.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific, Inc. is 6.93x versus 0.78x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMLRSemler Scientific, Inc.6.93x 7.65x $7.5M $16.9M XTNTXtant Medical Holdings, Inc.0.78x 69.62x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 7
Western Digital Corp. [WDC] is down 8.88% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 2.99% over the past day.
